Cidara Therapeutics, Inc. (CDTX)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Jeffrey L. Stein Ph.D. | President, CEO & Executive Director | 603.7k | -- | 1955 |
| Dr. Kevin M. Forrest Ph.D. | Founder and Chief Strategy Officer | 333.31k | -- | 1977 |
| Ms. Allison Lewis CCP, SPHR | Senior Vice President of People & Culture | -- | -- | -- |
| Ms. Laura A. Navalta | Senior Vice President of Clinical Operations | -- | -- | -- |
| Dr. Nicole Davarpanah J.D., M.D. | Senior VP of Translational Research & Development | -- | -- | -- |
Cidara Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 69
Description
Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.
Corporate Governance
Recent Events
- Apr 24, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Apr 23, 2024S-8: Offering RegistrationsSee Full Filing
- Apr 22, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Apr 16, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Apr 05, 20248-K: Corporate Changes & Voting MattersSee Full Filing